surgery as a contemporary therapeutic modality for head and neck cancer southern ohio medical center...
TRANSCRIPT
![Page 1: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/1.jpg)
Surgery as a ContemporaryTherapeutic Modality
for Head and Neck Cancer
Southern Ohio Medical Center Grand Rounds
May 16, 2008
David E. Schuller, M.D.
Vice President, Medical Center Expansion and Outreach
Professor, Department of Otolaryngology –Head and Neck Surgery
John W. Wolfe Chair in Cancer Research CEO Emeritus, The James
Director Emeritus, Comprehensive Cancer Center
![Page 2: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/2.jpg)
![Page 3: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/3.jpg)
![Page 4: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/4.jpg)
![Page 5: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/5.jpg)
![Page 6: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/6.jpg)
Master Plan - 2016
![Page 7: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/7.jpg)
Cancer in Ohio
Cancer is the #1 killer in Ohio10th highest rate in US for cancer deaths for women13th highest rate in US for cancer deaths for men6th highest death rate for breast cancer6th highest death rate for colorectal cancerEvery hour of every day, 7 people in Ohio are diagnosed with cancerEvery hour of every day, 3 people in Ohio die from cancer
![Page 8: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/8.jpg)
Cancer in Ohio
Based on American Cancer Society estimates, medical expenditures for cancer cases diagnosed in Ohio annually exceed $1 billion; furthermore, total annual costs, including lost productivity, exceed $8 billion.
Source: Ohio Cancer Incidence Surveillance System Status Report, 2003, Ohio Department of Health, April 2004
![Page 9: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/9.jpg)
Cancer in Ohio
0
100,000
200,000
300,000
400,000
500,000
600,000
700,000
800,000
900,000
1,000,000
1-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
Age
Po
pu
latio
n
Ohio Population, 2004 Estimate Ohio Population, 2000 Census
2010
Ohio’s population is aging
Source: U.S. Census Bureau, March 2005
![Page 10: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/10.jpg)
Source: Ohio Department of Health Data 2004, U.S. Census Bureau 2004, KSA Analysis
0
3000
6000
9000
0-4 '5-9 '10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
0
500
1000
1500
2000
2500
2001 Number of Cancer Cases
Cancer Incidence
Nu
mb
er
of
ca
nc
er
ca
se
s
Ca
nc
er In
cid
en
ce
Ra
te / 1
00
,00
0
2001 Ohio Cancer Cases and Incidence
Cancer in Ohio
Cancer incidence increases as the population ages
![Page 11: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/11.jpg)
OSU Comprehensive Cancer Center
NCI designated “Comprehensive” since 1976One of only 39 comprehensive cancer centers in the USAOnly 1 of 5 cancer centers in nation with special NCI Phase I and Phase II contracts for clinical trials 250 cancer investigators in 15 of the 19 collegesGenerates, on average, more than $100M annually in cancer-relevant research funding
The OSU Cancer Program
![Page 12: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/12.jpg)
James Cancer Hospital and Solove Research Institute
Research teaching hospital training the doctors of tomorrowOnly free-standing cancer hospital in Ohio One of only 10 hospitals exempt from Medicare Prospective Payment System (PPS) Founding member of National Comprehensive Cancer Network (NCCN)
The OSU Cancer Program
![Page 13: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/13.jpg)
Background Information
Therapeutic Options
1. Surgery – locoregional
2. Radiotherapy – locoregional
3. Chemotherapy – Systemic
4. Chemoradiotherapy – locoregional
![Page 14: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/14.jpg)
BackgroundHead and Neck Cancer
Survival Improvement NO
Failure Site*Local/Regional 23%Distant 18%
*Laramore, et al., Int. J. Rad. Onc. Biol. Phys., 23(4), 1992
![Page 15: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/15.jpg)
BackgroundHead and Neck Cancer
Quality of Life ImprovementProbably
Patient ComplianceMajor Challenge (36%)*
*Laramore, et al., Int. J. Rad. Onc. Biol. Phys., 23(4), 1992
![Page 16: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/16.jpg)
![Page 17: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/17.jpg)
![Page 18: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/18.jpg)
Definition of Terms
Phase I Trial - ToxicityRecurrent/metastatic, any type/site
Phase II Trial - ResponseRecurrent/metastatic, type/site specific
Phase III Trial - SurvivalPreviously untreated, controlled, randomized
![Page 19: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/19.jpg)
Research Capabilities
Single Institutions Pilot Studies
Individual Cooperative Group Phase I/II Trials
Multiple Cooperative Groups (HNI) Phase III Trials
![Page 20: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/20.jpg)
Treatment Modalities
Surgery
Radiation Therapy
Chemotherapy
Chemoradiotherapy
. . . Non-specific “bigger is better”
![Page 21: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/21.jpg)
Tx Modalities in New Millennium
Surgery organ preservation/ reconstructive techniques
Radiation Therapy conformal, intraoperative, intensity modulated
Chemotherapy molecular targeted therapies
. . . specific and focused
![Page 22: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/22.jpg)
Advanced Stage Head & Neck Cancer
Conventional therapy (S + RT) 38% 4 yr survival*
Improved locoregional control failure at distant sites
Patient non-compliance compromises ability to improve survival rates
*Kramer et al, Head and Neck Surg. 1987
![Page 23: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/23.jpg)
Head and Neck Intergroup Study 0034*
• Phase III Trial– Surgery + RT vs. Surgery + sequential CT/RT
• No survival improvement
• Decreased distant metastases– 15% vs. 23% (p = 0.03)
• High failure rates– local 15.3%– regional 9.5%– distant 14.9%
* Laramore, et al., Int J Radiat Oncol Biol Phys., 1992
![Page 24: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/24.jpg)
Problems
• High rate of disease recurrence
• No survival advantage with addition of chemotherapy
• Poor patient compliance– Head and Neck Intergroup Study 0034*
• only 42% completed all treatment on experimental arm• patient refusal - most common reason
*Laramore, et al., Int J Radiat Oncol Biol Phys., 1992
![Page 25: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/25.jpg)
Goals of Intensification Regimen
Intensify treatment to primary tumor, neck nodes and distant sites
Improve patient compliance
Assess toxicity related to therapy
![Page 26: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/26.jpg)
Intensification Schema
• Eligibility– previously untreated, resectable SCC of oral cavity, oropharynx
or hypopharynx
– Clinical Stage III or IV ( or Stage II of hypopharynx)
– Karnofsky Performance Status > 60
• Preop: accelerated, fractionated chemoradiotherapy
• Surgical resection + intraoperative RT (IORT)
• Postop: concurrent chemoradiotherapy
![Page 27: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/27.jpg)
IORT
• Directly visualized boost to area of surgical margins– Greatest benefit to negative or microscopically
positive margins
• Spares surrounding normal tissues
• Accelerates treatment time
• No increase in perioperative complications*
• Split-course XRT*Haller, et al., Am J Otolaryngol., 1996
![Page 28: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/28.jpg)
Day 1 5,6,7,8 8 29+ 50+Endoscopy X& biopsy
Surgery X
IORT X (7.5 Gy)
EBRT X X X (B.I.D.- total 9.1 Gy)
Cisplatin X X (80mg/m2) (100mg/m2)
Schema - Intensification I
![Page 29: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/29.jpg)
RESULTS - Intensification I*
N = 37
Median time at risk = 21 months
Compliance– Patient = 92% (34/37) – Protocol = 81% (30/37)
*Schuller et al, Arch Otolaryngol Head Neck Surg. 1997
![Page 30: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/30.jpg)
RESULTS - Intensification I*
Loco-regional control– Overall = 97% (1/37) (local recurrence)– Completing protocol = 100% (0/30)
Distant metastases = 16% (6/37)– Overall = 16% (6/37)– Completing protocol = 17% (5/30)
*Schuller et al, Arch Otolaryngol Head Neck Surg. 1997
![Page 31: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/31.jpg)
RESULTS - Intensification I*(Long-term follow-up)
Median time at risk = 40 months
Local control = 97% (36/37)
Regional nodal control = 95% (35/37)
Distant metastasis = 19% (7/37)
4-year overall survival = 45.9%
*Grecula, et al., Cancer Investigation. 2001
![Page 32: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/32.jpg)
Schema – Intensification III
IR II acute hematologic toxicities unacceptable
IR III modifications– Weekly paclitaxel 45 mg/m2 over 3 hrs.
• Begin POD #6• 9 cycles total
– Postop cisplatin 30 mg/m2 per day for 3 days• 2 cycles total - 21 days apart• Begin POD #27
![Page 33: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/33.jpg)
Day 1-4 4 10 31 32Surgery X
IORT X (7.5 Gy)
EBRT X X X
7 B.I.D. x (total 9.2 Gy)
Cisplatin X X (30mg/m2) (30mg/m2)
Paclitaxel X (45mg/m2 weekly x 9)
Schema - Intensification IV
Total Duration of Treatment = 52 Days
![Page 34: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/34.jpg)
Tumor Site (N=43)
Oropharynx: 46% (20)
Oral cavity: 35% (15)
Hypopharynx: 19% (8)
Overall Stage (N=43)
Stage III: 28% (12)
Stage IV: 72% (31)
![Page 35: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/35.jpg)
T and N Distribution of the Enrolled Patients
N0 N1 N2a N2b N2c N3 Total
T1 1 1
T2 1 2 1 4
T3 6 5 3 2 2 4 22
T4 5 4 2 1 1 3 16
Total 11 10 6 5 3 8 43
![Page 36: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/36.jpg)
RESULTS - Intensification IV
N = 43
Median time at risk = 45 months (10.4 – 56.2)
Compliance– Total Protocol = 53% (23/43)– Patient = 80% (34/43)
Patients not completing protocol– Toxicity = 10 (23%)– Non-cancer death = 1 (2%)– Patient non-compliance = 9 (20%)
![Page 37: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/37.jpg)
Copyright restrictions may apply.
Schuller, D. E. et al. Arch Otolaryngol Head Neck Surg 2007;133:320-326.
![Page 38: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/38.jpg)
RESULTS - Intensification IV
Overall loco-regional control = 93% (40/43)
Distant metastases– Overall = 9.3% (4/43)– Completing total protocol = 8.7% (2/23)
![Page 39: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/39.jpg)
Toxicities of the Regimen (N=43)
Operative Toxicity
Type of Toxicity
Acute Late
Grade-3 Grade-4 Grade-5 Grade-3 Grade-4 Grade-5
Pharyngeal fistula 1 5
Flap hematoma 1
Flap donor site dehiscence 1
Flap survival failure 1
*Schuller, et al., Cancer, June 2002: 94-12, 3169-3178.
![Page 40: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/40.jpg)
Toxicities of the Regimen (N=43)
Nonoperative Toxicity
Type of Toxicity
Acute Late
Grade-3 Grade-4 Grade-5 Grade-3 Grade-4 Grade-5
Hematologic 9
Infections requiring hospitalization 3 1
Mucositis 19
Gastrointestinal 14 1 1
Cardiovascular 2 1 1
CVA 4
Neuropathy 1
Xerostomia
Hearing loss 1
*Schuller, et al., Cancer, June 2002: 94-12, 3169-3178.
![Page 41: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/41.jpg)
Schuller, D. E. et al.Arch Otolaryngol Head Neck Surg 2007;133:320-326.
Kaplan-Meier survival analysis of intensification regimen 1
![Page 42: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/42.jpg)
Schuller, D. E. et al. Arch Otolaryngol Head Neck Surg 2007;133:320-326.
Kaplan-Meier survival analysis of intensification regimen 2
![Page 43: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/43.jpg)
Schuller, D. E. et al. Arch Otolaryngol Head Neck Surg 2007;133:320-326.
Kaplan-Meier survival analysis of intensification regimen 3
![Page 44: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/44.jpg)
Functional Outcomes
• Speech – 100%– Laryngeal 88% (38/43)– Vocal prosthesis 12% (5/43)
• Swallowing (N = 35 > 12 months NED)– Regular diet 71% (25/35)– Soft diet 20% (7/35)– No P.O. intake 9% (9/35)
• Permanent Tracheotomy - 0
![Page 45: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/45.jpg)
Future Studies
Quality of life/functional outcome measures
Multi-institutional limited group Phase II
Phase III trial
![Page 46: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/46.jpg)
Will survival improve using intensified therapy with acceptable toxicities or
do we need to look for alternative therapeutic approaches?
![Page 47: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/47.jpg)
Improved Therapy for Head and Neck Cancer --
-- more surgery?
-- more radiotherapy?
-- more chemotherapy?
. . . unlikely
![Page 48: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/48.jpg)
Improved Therapy for Head and Neck Cancer --
-- better surgery
-- better radiotherapy
-- better chemotherapy
. . . yes
![Page 49: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/49.jpg)
We need more effective drugs.
![Page 50: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/50.jpg)
There Is Tremendous Excitement About the Development of Targeted
Therapies for Patients
And genomics promises us more targets!!
![Page 51: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/51.jpg)
5-Year # Approved/ % Period # Taken Into Trials Approved
1978-1983 3/26 8%
1984-1989 9/34 26%
1990-1995 11/24 46%
1996-2001 14/23* 61%
2002-2003 * *
Percent Of Agents Which We Have Taken Into Initial Phase I Trials In Patients Which Have
Been Approved by the FDA
* Too early. Best predictor for success: a new mechanism of action.
Source: D. Von Hoff, May, 2003.
![Page 52: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/52.jpg)
Misinformation Among Non-Surgical Oncologists
• Non-surgical treatment organ preservation– Anatomic organ preservation organ function
preservation
• Misinformation about surgical resection– Laryngeal cancer total laryngectomy aphonia
– Tongue base cancer total glossectomy total laryngectomy
– Partial/total pharyngectomy permanent and total swallowing disability
![Page 53: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/53.jpg)
Surgical Organ FUNCTION Preservation
• Speech– Vocal cord paralysis after vagus nerve resection
Injections Laryngoplasty
• Partial laryngeal resection techniques– Endoscopic laser vaporization– Hemilaryngectomy w/laryngoplasty– Laser supraglottic laryngectomy– Supracricoid laryngectomy– Partial cricoid resection
• Total laryngectomy– Vocal restoration
Result:: useful speech and swallowing (with aspiration)
![Page 54: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/54.jpg)
Surgical Organ FUNCTION Preservation
• Swallowing– Partial oral/pharyngeal defects – flaps and/or
grafts1,2
Result: useful swallowing (with aspiration) and speech
1Stein and Schuller, Laryngoscope, 1989.2Alvi and Myers, et al., Head Neck, 1996.
![Page 55: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/55.jpg)
Surgical Organ FUNCTION Preservation
• Speech and Swallowing– Partial laryngopharyngeal defects – flaps
(MC or free)1, 2
– Total laryngopharyngeal defects – flaps (free)3, 4, 5
Result: useful swallowing (with aspiration) and speech1Urken, et al., Arch Otolaryngol., 1997.2Schuller, et al., Laryngoscope, 1997.3Varvares, et al., Head Neck, 2000.4Jones, et al., Ann Plast Surg., 1996.5Rogers, et al., Head Neck, 2004.
![Page 56: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/56.jpg)
Concerns about Non-Surgical Organ Preservation Therapy
• Larynx VA study sustained survival with organ preservation
• Non-laryngeal sites multiple phase II studies1,2
• Goal?– Organ preservation vs. organ preservation with
improved survival?
• Different biological systems Larynx OC, ORO, HYPO
5 yr. Survival 65-70% 30-35%
• For non-laryngeal sites, is it currently justifiable/ethical to offer non-surgical organ preservation therapy based on phase II data with minimal chance of improving survival?
1Roca, Eur J. Cancer, 1996.2Fuwa, Nippon Igaku Hoshasen Gakkai Zasshi, 2002.
![Page 57: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/57.jpg)
Organ Preservation Strategies
• Laudable, need to continue to study• Optimal goal function preservation and
survival improvement• Maximally aggressive utilization of –
– Surgery– Radiotherapy– Chemotherapy
...unacceptable toxicities and non- functioning/absent organs
• Need to recognize value of all modalities and develop trials using all modalities optimal results
![Page 58: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/58.jpg)
Is clinical research worth the high cost?
Advanced Non-Hodgkins Lymphoma*
Standard Therapy: CHOP
30% survival (cooperative groups)
Newer Therapies:
m-BACOD (single institution)
ProMACE-CytaBOM (single institution)
MACOP-B (single institution)
*Fisher, et al., NEJM, 328, 1993
55-65%survival
![Page 59: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/59.jpg)
Is clinical research worth the high cost?
But….limited follow-up, difficult administration, more toxic, more costly
SWOG, ECOG Phase III Trial 1985 1138 patients 899 eligible
ConclusionsNo improvement to survivalSlight increase in fatal toxic reaction (p = .09)CHOP still best available treatment*
*Fisher, et al., NEJM, 328, 1993
![Page 60: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/60.jpg)
Acknowledgements
Amit Agrawal, M.D.Enver Ozer, M.D.
John Grecula, M.D.Chris Rhoades, M.D.
![Page 61: Surgery as a Contemporary Therapeutic Modality for Head and Neck Cancer Southern Ohio Medical Center Grand Rounds May 16, 2008 David E. Schuller, M.D](https://reader034.vdocuments.mx/reader034/viewer/2022051620/56649e865503460f94b88c79/html5/thumbnails/61.jpg)
Thank you
for
this honor.